colchicine and simvastatin

Both colchicine and simvastatin have myotoxic potential. Additionally, colchicine may inhibit the metabolism of simvastatin via CYP3A4 and P-glycoprotein, leading to elevated simvastatin plasma concentrations. The combined effect increases the risk of skeletal muscle toxicity.

Patients may develop myopathy, manifesting as muscle pain, tenderness or weakness, with elevated creatine kinase levels. Progression to rhabdomyolysis can occur, with risk of acute renal failure and potentially fatal outcomes. The risk is higher in patients with renal or hepatic impairment.

Avoid concomitant use where possible. If the combination is necessary, use the lowest effective doses and monitor for muscle symptoms and serum creatine kinase. Consider alternative statins that are not metabolised by CYP3A4, such as pravastatin or rosuvastatin. In patients with renal impairment, dose adjustment of colchicine is essential.

Well documented in case reports and pharmacokinetic studies. Clinical guidelines list this interaction as significant. No randomised controlled trials have specifically assessed this combination.